Court rejects patent infringement claims in covid-19 sham litigation case
Credit: iStock.com/baytunc
A covid-19 test manufacturer accusing a rival of sham litigation to monopolise the market for genetic testing using saliva has proven it did not infringe upon any patents, but its new antitrust claims are barred by the First Amendment, a California federal court has ruled.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10